Get the Weekly Intelligence Brief — top committee picks every Sunday.

GMED vs IONS

Globus Medical vs Ionis Pharmaceuticals, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
MetricGMEDIONS
AI Score 71 43
Price $85.12 $55.38
P/E Ratio 21.45× -16.02×
ROE 11.8% -77.9%
Revenue Growth YoY
Gross Margin 68.5% 98.2%
Debt / Equity 0.02× 5.50×
Dividend Yield 0.0% 0.0%
RSI (14) 75.9 46.6
Beta 0.954 0.4
Expected Upside +0.1%

AI Committee View

Current Innellis committee reasoning for GMED versus IONS.
GMED leads by 28 points.

GMED scores 71/100 (Buy) versus IONS at 43/100 (Reduce).

GMED Committee View
75% agreement
4 analysts

The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • RSI at 76 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
IONS Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • MACD histogram positive -- bullish momentum — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price-to-book of 26.2x prices in significant intangible value — Value
  • ROE of only -110.9% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
GMED Full Analysis IONS Full Analysis